Another estimate-topping quarter for relentless Vertex

7 May 2024

US biopharma Vertex Pharmaceuticals (Nasdaq: VRTX) remains an evergreen pick in the stock market, announcing another set of financial results that exceeded expectations.

The company came out with quarterly earnings - adjusted for non-recurring items- of $4.76 per share, beating the Zacks consensus estimate of $4.10 per share and way ahead of the $3.05 figure from the first quarter of 2023.

"A strong start to 2024"It is the fourth time in as many quarters that Vertex has exceeded analysts’ expectations with its earnings.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK